Stenting of renal artery stenosis preserves renal function in both diabetic and nondiabetic patients with chronic renal insufficiency  by Subramanian, Rajesh et al.
JACC March 19,2003 ABSTRACTS - Angiography & Interventional Cardiology 
Results: ISR was seen in 83 of 212 (39%) stented lesions. Of predictive value were 
presence of diabetes mellitus (P~0.04) as well as cumulative time of inflations (P=O.Ol) 
as procedural determinants. Angiographic progression was found in 12 of 129 (9%) pri- 
marily untreated lesions. Progression of a normal segment or regression were not seen. 
Progression of native plaques was associated with presence of ISR in 11 cases and with 
absence of ISR in 1 case (P=O.Ol). Smoking (PcO.02) turned out predictive for plaque 
progression. whereas medication and procedural angiographic parameters did not. Nota- 
bly, 9 of 11 (82%) patients with progression presented with acute coronary syndromes at 
follow-up. 
Conclusion: The findings of the present pilot study show that restenosis of a target 
stenosis following stent implantation IS associated with progression of other untreated 
lesions, and thereby suggest that both arteriosclerosis forms share common systemic 
pathogemc mechanisms. With presence of ISR, angiography of primarily untreated coro- 
naries should be performed, especially in case of preexisting plaques. 
Gianturco coil). Moderate sized devices were used more frequently (1 patient recerved 
the 514 device; 2 the 614; 22 the 816; 7 the 1018; 3 the 12/10; 1 the 14112 and 1 patient 
received the 16114 mm device). Complete angiographic closure was seen immediately 
after device deployment in 29 out of 36 (81%) patients. At 24 hours, complete closure as 
evidenced by color Doppler echocardiography was demonstrated in 34 out of 36 (94%) 
patients. The remaining two patients had small residual shunt. At 6-month and l-year fol- 
low-up, complete closure was demonstrated in 35 out of 36 (97%) patients. In the two 
patients with small residual shunts at 24 hours post-procedure, one patient demonstrated 
complete closure by echocardiography at 6.months post-procedure. The other patient 
had no available follow-up. No complications related to device implantation occurred in 
any patient. 
Conclusions: Closure of PDA using the ADO is safe and effective in adult patients 
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Background: Patients with a patent foramen wale (PFO) and paradoxical embolism are 
at risk for recurrent thromboembolic events. We report the results of Phase 1 US clinical 
trial of patients who underwent transcatheter PFO closure for secondary prevention of 
paradoxical embolism using the AmplatzeK@ PFO occlude, (APO). 
Methods: From March 2000 through May 2002, 50 patients (28 males and 22 females) 
with PFO and at least 1 paradoxical embolic event were referred for transcatheter PFO 
closure using the APO. The median age was 41 yr. (range 15 - 61 yr.) and the median 
weight was 81 kg (range 45 - 118). Thlrty-six patients had cryptogenic stroke, 10 
patients had transient ischemic attack and 4 patients had peripheral embolism. Seven- 
teen patients had both a PFO and an atrial septal aneurysm. 
Results: Of 50 patients referred for closure, 49 underwent attempted closure of their PFO 
using the APO; one patient did not have a PFO. Fifty devices were successfully deployed 
I” all 49 patients (one patient received two devices for two separate fenestrations). 
Immediate complete closure es documented by transesophageal echocardiography 
(TEE)“no passage of bubbles from right to left atrium dunng Valsalva” was achieved in 
26/49 (53%) patrents and at 24 hours, by transthoracic echocardiography (TTE) was 
achieved in 31 (63%) patients. The median fluoroscopy time was 10.5 minutes (range 2.6 
- 43) and the median procedure time was 85.5 minutes (range 18 - 309). Complications 
encountered during and within the follow-up period included one patient who developed 
a hem&ma and an AV fist& requiring surgery and two patients who developed atrial 
fibrillation. At 3.month follow-up. 44 patients had a TrE with contrast bubble study, 38 
(86%) had complete closure. At a median follow-up interval of one year (range one 
month-569 days), there have been no recurrent embolic events. 
Conclusion: Transcatheter closure of PFO using the APO seems to be a safe and effec- 
twe therapy in the prevention of thromboembolic events in patients with a history of pre- 
sumed paradoxical embolism. 
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Background: Surgical closure of patent ductus arteriosus (PDA) in adult patients may be 
problematic. Recently, transcatheter closure of PDA using the Amplatzer duct occluder 
(ADO) has been shown to be safe and efficacious. We present our experience with this 
device in the adult population. 
Methods: Between January 2000 and January 2002, forty-one adult patients (31 females 
and 10 males) with a PDA were referred for closure with the ADO. The median age was 
35.8 years (range 18 - 70.7). The median Qp/Qs was 1.4 (range 0.6 - 3.5). The median 
diameter of the pulmonary artery end (narrowest diameter) was 3.4 mm (range 1.5 - 10); 
the median diameter of the ampulla was 10.7 mm (range 3.0 - 32) and the median length 
was 10.8 mm (range 1.5 - 35) According to the Toronto classification, there were 33 
Type A PDA’s; 1 Type B; 1 Type C; 2 Type D and 4 Type. 
Results: Of forty-one patients. thirty-seven underwent attempted closure of their PDA 
using the ADO. In the remaining four patients, the PDA was small, and was closed using 
Gianturco coils. The device was successfully deployed in all but one patient (the ductus 
could not be crossed and the patient ultimately had successful PDA closure using a 
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BACKGROUND: Statins and anti-platelet therapy are beneficial in patients undergoing 
percutaneous coronary interventions. Minimal data exists on the effectiveness of statins 
and dual antiplatelet therapy in patients undergoing peripheral vascular interventions. 
METHODS: 79 patients underwent peripheral vascular interventions between Jan 2001- 
Feb 2002. Clinical, procedure, and out&me data were collected by use of a standardized 
form and follow-up by structured phone call > 6 months post-procedure. Multivariate 
logistic regression analysis was used to adjust for baseline characteristics and comorbid- 
ities and adjusted odds ratios were calculated for the composite of death, Ml and stroke 
at 6.months. 
RESULTS: Fourteen of the 79 patients (17.7 %) had one or more cllnical event (death, 
Ml or stroke). After adjustment for demographics and comorbidities, statin therapy 
(OR=0.21,95% Cl 0.05 - 0.86, p=O.O3) and clopidogrel therapy (OR=0.17, 95% Cl 0.04 - 
0.78, p=O.O2) were associated with a significant reduction of the composite event rate at 
6 months. 
CONCLUSIONS: In this study cohort of patients undergoing peripheral endovascular 
intervention, statin therapy and anti-platelet therapy with clopidogrel were each associ- 
ated with a significantly lower risk-adjusted cardiovascular event rate at six months fol- 
low-up. These preliminary findings offer logical targets for quality improvement. 
Multwariate predictors of major adverse cardiac events after penpheral mtervenfmns 
No event Event Adjusted Odds ratio (95% P 
(n=65) (ll=l4) Cl) V&C? 
Age 66.8* 10.1 69.5 * 11.4 1.02 (0.96-1.09) 0.41 
Serum 1.2 + 0.6 1.8 f 0.8 2.27 (0.86-5.66) 0.08 
creatinine 
Diabetes 29.6 % 35.7 % 1.80 (0.39-8.12) 0.40 
StatIn use 64.1 % 28.5 % 0.21 (0.05-0.86) 0.03’ 
Clopidogrel use 82.8 % 57.1 % 0.17 (0.04-0.78) 0.02’ 
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Background: Renal artery stenting has been shown to stabilize or improve renal function 
in a significant proportion of patients with atherosclerotic renovascular disease and 
impaired renal function. Whether diabetic (DM) patients obtain similar benefits as nondia- 
betic patients (NDM) is unknown. 
Methods: The renal function of 36 consecutive pabents wth bilateral renal artery 
stenoses (11 DM; 25 NDM) and renal insufficiency (serum creatinine >/= 1.5 mgidl) was 
analyzed by plotting the reciprocal of serum creatinine versus time in days before and 
after stenting. 
Results: All patients had deterioration of renal function prior to intervention. At 47.4 +I- 
31.2 months post intervention, renal function improved or did not change in 76% and 
worsened in 24% of NDM patients compared to 73% and 27% of DM patients respec- 
tively (p=NS). (Figure) 
Conclusion: Renal artery stenting is equally beneficial in DM and NDM patients with 
impaired renal function and atherosclerotic renal artery stenosis. 
